3rd Quarter - Report

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$1,880,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues relating to the tax treatment of nonprofits, including governance of nonprofit organizations.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
GREGG HAIFLEY —
RACHEL MARCUS —
CAROLINE POWERS —
RICHARD WOODRUFF —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); State, Dept of (DOS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); Labor, Dept of (DOL)

Health Issues HCR

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act.

Contacted: SENATE; Labor, Dept of (DOL); U.S. Trade Representative (USTR); Natl Institutes of Health (NIH); U.S. Agency for International Development (USAID); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); White House Office; Environmental Protection Agency (EPA); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 772 (115th), H.R. 820 (115th), S. 456 (115th), H.R. 1676 (115th), H.R. 1231 (115th), S. 292 (115th), S. 261 (115th), S. 693 (115th)

Medicare/Medicaid MMM

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the American Health Care Act, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller-Johnson repeal bill. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, Removing Barriers to Colorectal Cancer Screening Act; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Contacted: Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); White House Office; U.S. Agency for International Development (USAID); State, Dept of (DOS); U.S. Trade Representative (USTR)

Bills named: S. 479 (115th), H.R. 1628 (115th), H.R. 1017 (115th)

Budget/Appropriations BUD

Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act. Also, issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act.

Contacted: U.S. Agency for International Development (USAID); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); U.S. Trade Representative (USTR); Labor, Dept of (DOL)

Tobacco TOB

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Contacted: Environmental Protection Agency (EPA); Food & Drug Administration (FDA); White House Office; Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE; U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR)

Bills named: H.R. 1136 (115th), H.R. 564 (115th), S. 294 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.